News GSK to file Jemperli for rectal cancer after phase 3 readout GSK's pivotal AZUR-1 trial of Jemperli monotherapy to delay or eliminate surgery in pre-operative rectal cancer has delivered a positive result.
News EU warns of brain tumour risk with some contraceptives EU pharmaceutical safety advisers have said that commonly used contraceptives may carry a small risk of a type of brain cancer with prolonged use.
News Pay offer rejected as ICR researchers continue strike action Researchers at the UK Institute of Cancer Research have held historic strikes over pay, claiming they are missing meals and struggling to cover bills.
News Sleep apnoea drug firm Apnimed files for IPO Apnimed has joined the IPO queue on the Nasdaq, hoping to raise additional funding for its late-stage oral therapy for obstructive sleep apnoea.
News Non-profit DNDi preps phase 3 trials for dengue antibody Non-profit DNDi has licensed a dengue therapy from India's SII, paving the way for a phase 3 trial in Malaysia, Thailand, and Brazil.
News Bausch + Lomb drug fails in glaucoma, but a new use beckons Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to abandon BL117 for glaucoma.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.